Trevena, Inc. (TRVN) is “One to Watch”
Trevena, Inc. (NASDAQ: TRVN) is a clinical stage biopharmaceutical company focused on developing and delivering biased ligands to discover the next generation of GPCR targeted medicine. The company is focused on three product candidates: Oliceridine, for moderate to severe acute pain; TRV734, an oral use medicine for people in moderate, severe acute, and chronic pain; and TRV250, for those suffering from migraines. On November 7, 2016, Aegis Capital Corp. (http://nnw.fm/6qwiQ) initiated coverage on Trevena, Inc., offering the company a ‘Buy’ rating with a target price of $14. This rating was released soon after the company reported its third quarter 2016…







